Market Overview

UPDATE: Stifel Nicolaus Raises PT to $118 on Allergan on Solid 2013 Outlook

Share:
Related AGN
Allergan Says FDA Accepts Its NDA Filing Of Oxymetazoline HCI Cream 1.0%
Salesforce, Allergan, Intrexon: Fast Money Picks For May 24
FDA accepts Allergan's NDA for oxymetazoline HCl cream; action date H1 2017 (Seeking Alpha)

Stifel Nicolaus maintained Allergan (NYSE: AGN) with a Buy rating and raised the price target from $110.00 to $118.00.

Stifel Nicolaus noted, "2013 guidance was robust, with product sales of $5.9-6.2bn (Consensus at high end of range) and EPS between $4.75-4.83 (15-17% growth, Consensus $4.74). Notably, guidance excluded obesity intervention (discontinued business), indicating strength in all other business lines, namely Botox with iOAB launch. With Allergan's 10% topline growth and mid-teens EPS growth aspirations intact, we look ahead to multiple 2013 catalysts (Levadex and Voluma FDA decisions, and bimatoprost and DARPin developments). As Allergan continues to execute on its growth plans, we reiterate our Buy and raise our TP to $118 to incorporate recent acquisitions."

Allergan closed at $106.70 on Tuesday.

Latest Ratings for AGN

DateFirmActionFromTo
Apr 2016Piper JaffrayDowngradesOverweightNeutral
Apr 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Apr 2016Goldman SachsReinstatesBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!